Psoriasis-related Treatment Exposure and Hospitalization or In-hospital Mortality Due to COVID-19 During the First and Second Wave of the Pandemic: Cohort Study of 1 326 312 Patients in France

Overview

Journal Br J Dermatol

Publisher Oxford University Press

Specialty Dermatology

Date 2021 Jul 26

PMID 34310699

Citations 6

Authors

L Penso

R Dray-Spira

A Weill

M Zureik

E Sbidian

Affiliations

Soon will be listed here.

Abstract

Background: Data on treatment exposures for psoriasis and poor COVID-19 outcomes are limited.

Objectives: To assess the risk of hospitalization or in-hospital mortality due to COVID-19 by treatment exposure in patients with psoriasis.

Methods: All adults with psoriasis registered in the French national health-insurance (Système National des Données de Santé, SNDS) database between 2008 and 2019 were eligible. Two study periods were considered: 15 February to 30 June 2020 and 1 October 2020 to 31 January 2021, the first and second waves of the COVID-19 pandemic in France, respectively. Patients were classified according to their baseline treatment: biologics, nonbiologics, topicals or no treatment. The primary endpoint was hospitalization for COVID-19 using Cox models with inverse probability of treatment weighting. The secondary endpoint was in-hospital mortality due to COVID-19.

Results: We identified 1 326 312 patients with psoriasis (mean age 59 years; males, 48%). During the first study period, 3871 patients were hospitalized for COVID-19 and 759 (20%) died; during the second period 3603 were hospitalized for COVID-19 and 686 (19%) died. In the propensity score-weighted Cox models, risk of hospitalization for COVID-19 was associated with exposure to topicals or nonbiologics [hazard ratio (95% confidence interval): 1·11 (1·04-1·20) and 1·27 (1·09-1·48), respectively] during the first period, and with all exposure types, during the second period. None of the exposure types was associated with in-hospital mortality due to COVID-19.

Conclusions: Systemic treatments for psoriasis (including biologics) were not associated with increased risk of in-hospital mortality due to COVID-19. These results support maintaining systemic treatment for psoriasis during the pandemic.

Citing Articles

Enhanced impact of psoriasis severity on the treatment demands of patients during the COVID-19 pandemic: a cross-sectional study based on a national psoriasis registry in China.

Yang Z, Jin Y, Wang M, Li R, Li W, Li H BMJ Open. 2024; 14(2):e079627.

PMID: 38367975 PMC: 10875510. DOI: 10.1136/bmjopen-2023-079627.

The Relationship Between Psoriasis, COVID-19 Infection and Vaccination During Treatment of Patients.

Khanahmadi M, Khayatan D, Guest P, Hashemian S, Abdolghaffari A, Sahebkar A Adv Exp Med Biol. 2023; 1412:339-355.

PMID: 37378776 DOI: 10.1007/978-3-031-28012-2_18.

Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study.

Kolla E, Weill A, Desplas D, Semenzato L, Zureik M, Grimaldi L Vaccines (Basel). 2022; 10(11).

PMID: 36423033 PMC: 9694832. DOI: 10.3390/vaccines10111938.

Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?.

Komine M, Ansary T, Hossain M, Kamiya K, Ohtsuki M Int J Mol Sci. 2022; 23(20).

PMID: 36293117 PMC: 9603600. DOI: 10.3390/ijms232012260.

Profiles of copper intrauterine devices and levonorgestrel intrauterine systems users in France in 2019: A national observational population-based study.

Roland N, Baricault B, Dray-Spira R, Weill A, Duranteau L, Zureik M Int J Gynaecol Obstet. 2022; 160(2):594-603.

PMID: 36066002 PMC: 10087463. DOI: 10.1002/ijgo.14438.

References

Tuppin P, Rudant J, Constantinou P, Gastaldi-Menager C, Rachas A, de Roquefeuil L . Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017; 65 Suppl 4:S149-S167. DOI: 10.1016/j.respe.2017.05.004. View

Xu S, Ross C, Raebel M, Shetterly S, Blanchette C, Smith D . Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2009; 13(2):273-7. PMC: 4351790. DOI: 10.1111/j.1524-4733.2009.00671.x. View

Austin P, Stuart E . Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015; 34(28):3661-79. PMC: 4626409. DOI: 10.1002/sim.6607. View

Mahil S, Yates M, Langan S, Yiu Z, Tsakok T, Dand N . Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol. 2020; 185(1):80-90. PMC: 9214088. DOI: 10.1111/bjd.19755. View

Mahil S, Dand N, Mason K, Yiu Z, Tsakok T, Meynell F . Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2020; 147(1):60-71. PMC: 7566694. DOI: 10.1016/j.jaci.2020.10.007. View

Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G . Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. J Am Acad Dermatol. 2020; 83(1):285-287. PMC: 7194926. DOI: 10.1016/j.jaad.2020.04.085. View

Lebwohl M, Rivera-Oyola R, Murrell D . Should biologics for psoriasis be interrupted in the era of COVID-19?. J Am Acad Dermatol. 2020; 82(5):1217-1218. PMC: 7156810. DOI: 10.1016/j.jaad.2020.03.031. View

Yousaf A, Gayam S, Feldman S, Zinn Z, Kolodney M . Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study. J Am Acad Dermatol. 2020; 84(1):70-75. PMC: 7484805. DOI: 10.1016/j.jaad.2020.09.009. View

Baniandres-Rodriguez O, Vilar-Alejo J, Rivera R, Carrascosa J, Dauden E, Herrera-Acosta E . Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis. J Am Acad Dermatol. 2020; 84(2):513-517. PMC: 7587130. DOI: 10.1016/j.jaad.2020.10.046. View

10.

Nast A, Gisondi P, Ormerod A, Saiag P, Smith C, Spuls P . European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015; 29(12):2277-94. DOI: 10.1111/jdv.13354. View

11.

Castagne B, Viprey M, Caillet-Pascal P, Belhassen M, Desjeux G, Bailly S . [Algorithms to identify chronic inflammatory rheumatism and psoriasis in medico-administrative databases: A review of the literature]. Rev Epidemiol Sante Publique. 2021; 69(4):225-233. DOI: 10.1016/j.respe.2021.02.002. View

12.

Ward M, Gooderham M . Asymptomatic SARS-CoV2 infection in a patient receiving risankizumab, an inhibitor of interleukin 23. JAAD Case Rep. 2020; 7:60-61. PMC: 7645273. DOI: 10.1016/j.jdcr.2020.10.032. View

13.

Marques E, Paluch Z, Bohac P, Slanar O, Belacek J, Hercogova J . Epidemiology of moderate-to-severe psoriasis: a comparison between psoriasis patients treated with biological agents, conventional systemic drugs and topical agents. J Dermatolog Treat. 2020; 33(3):1435-1448. DOI: 10.1080/09546634.2020.1826393. View

14.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

15.

Egeberg A, Mallbris L, Gislason G, Skov L, Hansen P . Risk of Multiple Sclerosis in Patients with Psoriasis: A Danish Nationwide Cohort Study. J Invest Dermatol. 2016; 136(1):93-8. DOI: 10.1038/JID.2015.350. View

16.

Balestri R, Rech G, Girardelli C . SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor. J Eur Acad Dermatol Venereol. 2020; 34(8):e357-e358. PMC: 7267317. DOI: 10.1111/jdv.16571. View

17.

Penso L, Dray-Spira R, Weill A, Zureik M, Sbidian E . Drop in biological initiation for patients with psoriasis during the COVID-19 pandemic. Br J Dermatol. 2021; 185(3):671-673. PMC: 8250964. DOI: 10.1111/bjd.20406. View

18.

Tuppin P, Drouin J, Mazza M, Weill A, Ricordeau P, Allemand H . Hospitalization admission rates for low-income subjects with full health insurance coverage in France. Eur J Public Health. 2010; 21(5):560-6. DOI: 10.1093/eurpub/ckq108. View

19.

Rey G, Jougla E, Fouillet A, Hemon D . Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009; 9:33. PMC: 2637240. DOI: 10.1186/1471-2458-9-33. View

20.

Mason A, Mason J, Cork M, Dooley G, Hancock H . Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013; (3):CD005028. PMC: 11227123. DOI: 10.1002/14651858.CD005028.pub3. View